CABALETTA BIO INC. news, videos and press releases
For more news please use our advanced search feature.
CABALETTA BIO INC. - More news...
CABALETTA BIO INC. - More news...
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
- Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
- Cabaletta Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
- UPDATE - Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
- Cabaletta Bio Announces Updated Clinical Data Demonstrating Deepening Clinical Responses across Multiple Indications with Rese-cel at February Scientific Meetings
- Cabaletta Bio Announces Presentations Featuring Updated Clinical Data on Rese-cel at Upcoming Scientific Meetings in February
- Cabaletta Bio to Participate in Guggenheim’s SMID Cap Biotech Conference
- Cabaletta Bio Outlines Strategic Priorities and Anticipated Key Milestones for 2025
- Cabaletta Bio to Participate in Upcoming Investor Conferences in December
- Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024
- Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
- Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024
- Cabaletta Bio to Participate in Upcoming Investor Conferences in September
- Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum
- Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201
- Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
- Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update
- Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
- Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
- Cabaletta Bio to Participate in Upcoming Investor Conferences in March
- Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
- Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
- Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis
- Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference
- Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference
- Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
